What are the microbial components implicated in the pathogenesis of sepsis? Report on a symposium

Clinical Infectious Diseases

Volumn 31, Issue 4, 2000, Pages 851-858

  Horn, David L ^a   Morrison, David C ^b   Opal, Steven M ^c   Silverstein, Richard ^d   Visvanathan, Kumar ^e   Zabriskie, John B ^e  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^e ockefeller University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; BACTERIAL DNA; BLOOD CLOTTING FACTOR; BRADYKININ; COMPLEMENT; CYTOKINE; ENDOTOXIN; LEUKOTRIENE; NITRIC OXIDE; PEPTIDOGLYCAN; PROSTAGLANDIN; REACTIVE OXYGEN METABOLITE; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD CLOTTING; COMPLEMENT SYSTEM; FIBRINOLYSIS; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; IMMUNE RESPONSE; INFLAMMATION; MEDIATOR RELEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK;

AMINO ACID SEQUENCE; ANIMALS; CARBOHYDRATE SEQUENCE; DISEASE MODELS, ANIMAL; DNA, BACTERIAL; ENDOTOXINS; GRAM-POSITIVE BACTERIA; HUMANS; INFLAMMATION MEDIATORS; LIPID A; MODELS, BIOLOGICAL; PEPTIDOGLYCAN; SEPSIS;

EID: 0034450683     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/318127     Document Type: Article

References (64)

1. Antibiotics, cytokines, and endotoxin: A complex and evolving relationship in gram-negative sepsis
2. Lessons learned in recent clinical trials for sepsis
3. The in vivo significance of antibiotic-induced endotoxin release in experimental gram-negative sepsis
4. Clinical gram-positive sepsis: Does it fundamentally differ from gram-negative sepsis?
5. Lipopolysaccharide and peptidoglycan: CD-14-dependent bacterial inducers of inflammation
6. Bacterial DNA causes septic shock
7. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
8. CpG motifs in bacterial DNA trigger direct B-cell activation
9. CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract
10. Superantigen and endotoxin synergize in the induction of lethal shock
11. Comparative study of cytokine release by human peripheral blood mononuclear cells stimulated with Streptococcus pyogenes superantigenic toxins, heat-killed streptococci, and lipopolysaccharide
12. Immunotherapy of endotoxemia and septicemia
13. Therapeutic intervention in sepsis with antibody to endotoxin: Is there a future?
14. Bacterial endotoxin: Molecular relationships of structure to activity and function
15. Phylogenetic perspectives in innate immunity
16. Lessons learned from clinical trials of sepsis
17. Endotoxin-related intracellular pathways: Implications for therapeutic intervention
18. Bacterial endotoxin: Chemical constitution, biological recognition, host response, and immunological detoxification
19. Antibacterial agents that inhibit lipid A biosynthesis
20. Antibacterial agents specifically inhibiting lipopolysaccharide synthesis
21. A non-covalent complex vaccine prepared with detoxified E. Coli J5 LPS and Neisseria meningitidis group B outer membrane protein produces protective antibodies against gram-negative bacteria
22. Structural and functional organization of the human neutrophil 60-kDa bactericidal/permeability-increasing protein
23. Bactericidal/permeability-increasing protein and host defense against gram-negative bacteria in endotoxin
24. Crystal structure of human BPI and two bound phospholipids at 4.5 angstrom resolution
25. 21 in children with severe meningococcemia
26. Extracorporeal removal of endotoxin in the septic patients by toraymyxin: Clinical results in a phase II and III study in Japan
27. Endotoxin eliminating therapy in patients with severe sepsis-direct hemoperfusion using polymyxin B immobilized fiber column
28. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein
29. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins
30. In vivo protection against endotoxin by plasma high density lipoprotein
31. Lipopolysaccharide antagonists
32. Cytokine induction by LPS corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS
33. E5531: A pure endotoxin antagonist of high potency
34. Endotoxin-mediated endothelial cell injury and activation: Role of soluble CD14
35. CD14 as a pattern recognition receptor
36. CD14 and innate recognition of bacteria
37. Antibodies against CD14 protect primates from endotoxin-induced shock
38. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
39. Potential hazards of combination immunotherapy in the treatment of experimental sepsis
40. Treatment of septic shock with tumor necrosis factor receptor: Fc fusion protein
41. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: Effect of timing of recombinant human IL-10 administration
42. Endotoxin in human disease. II. Biologic effects and clinical evaluations of anti-endotoxin therapies
43. Binding of peptidoglycan to CD14
44. Gram-positive cell walls stimulate synthesis of tumor necrosis factor α and interleukin-6 by human monocytes
45. The staphylococcal enterotoxins and their relatives
46. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A
47. Staphylococcus-mediated T-cell activation and spontaneous natural killer cell activity in the absence of major histocompatibility complex class II molecules
48. Immunologic cross-reactivity of type A streptococcal exotoxin (erythrogenic toxin) and staphylococcal enterotoxins B and Cl
49. Neutralization of streptococcal pyrogenic exotoxins and staphylococcal enterotoxins by antisera to synthetic peptides representing conserved amino acid motifs
50. Enhancement of endotoxic shock by N-acetylmuramyl-1-alanyl-(1-seryl)-d-isoglutamine (muramyl dipeptide)
51. Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans
52. Roles of the bacterial cell wall and capsule in induction of tumor necrosis factor α by type III group B streptococci
53. The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure
54. Disseminated intravascular coagulation associated with Staphylococcus aureus septicemia is mediated by peptidoglycan-induced platelet aggregation
55. Streptococcal cell walls and synovial cell activation
56. Structural characteristics of peptidoglycan fragments required to prime mice for induction of anaphylactoid reactions by lipopolysaccharides
57. Antibody levels to bacterial peptidoglycan in human sera during the time course of endocarditis and bacteremic infections caused by Staphylococcus aureus
58. Antibiotic-induced release of lipoteichoic acid and peptidoglycan from Staphylococcus aureus: Quantitative measurements and biological reactivities
59. Intact and denatured bacterial DNA-induced lethality in a murine model of experimental septic shock
60. Cutting edge: Bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages
61. From the bench to the bedside: The future of sepsis research - Executive summary of an American College of Chest Physicians
62. Selected treatment strategies for septic shock based upon proposed mechanisms of pathogenesis
63. Immunotherapy with antibodies to core lipopolysaccharide: A critical appraisal